anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Transcriptional dysregulation is a hallmark of cancer, and several transcriptional regulators have been demonstrated to contribute to cancer progression. In this study, we identified an upregulation of the transcriptional corepressor downregulator of transcription 1-associated protein 1 (DRAP1) in TNBC, which was closely associated with poor recurrence-free survival in patients with TNBC. DRAP1 promoted TNBC proliferation, migration, and invasion in vitro and tumor growth and metastasis in vivo. Mechanistically, the downregulator of transcription 1 (DR1)/DRAP1 heterodimer complex inhibited expression of the cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1) and thereby increased activation of mTOR, which sensitized TNBC to treatment with the mTOR inhibitor everolimus. DRAP1 and DR1 also formed a positive feedback loop. DRAP1 enhanced the stability of DR1 by recruiting the deubiquitinase USP7 to inhibit its proteasomal degradation; in turn, DR1 directly promoted DRAP1 transcription. Collectively, this study uncovered a DRAP1-DR1 bidirectional regulatory pathway that promotes TNBC progression, suggesting that targeting the DRAP1/DR1 complex might be a potential therapeutic strategy to treat TNBC. Significance: DR1 and DRAP1 form a positive feedback loop and a repressor complex to cooperatively inhibit cytosolic arginine sensor for mTORC1 subunit 1 transcription and stimulate mTOR signaling, leading to progression and increased everolimus sensitivity in triple-negative breast cancer.
Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
Patient participants will have a diagnosis of mild cognitive impairment or prodromal / mild Alzheimer's Disease. Participants with a global CDR score of 0.5 and 1 will be recruited in a minimum of a 2:1 ratio respectively in the study.
BREZTRI AEROSPHERE should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. BREZTRI AEROSPHERE has not been studied in patients with acutely deteriorating COPD. The use of BREZTRI AEROSPHERE in this setting is not appropriate.

BREZTRI AEROSPHERE should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. BREZTRI AEROSPHERE has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

When beginning treatment with BREZTRI AEROSPHERE, patients who have been taking inhaled, short-acting beta2-agonists on a regular basis (e.g., four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. When prescribing BREZTRI AEROSPHERE, the healthcare provider should also prescribe an inhaled, short acting beta2-agonist and instruct the patient on how it should be used. Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated. 

COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If BREZTRI AEROSPHERE no longer controls symptoms, or the patient’s inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalations of short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting, re-evaluate the patient and the COPD treatment regimen at once. The daily dosage of BREZTRI AEROSPHERE should not be increased beyond the recommended dose.
BACKGROUND: Visceral leishmaniasis (VL), or kala-azar, is a common comorbidity in patients with AIDS in endemic areas. Many patients continue to experiences relapses of VL despite virological control, but with immunological failure. These patients remain chronically symptomatic with hypersplenism, for example with anemia, leukopenia, and thrombocytopenia, and are at risk of severe co-infection due to low CD4+ count. Therefore, in this study, splenectomized patients with VL and HIV infection were investigated to understand why the CD4+ count fails to recover in these patients, evaluating the importance of spleen mass for hypersplenism and immunological failure.
METHODS: From a retrospective open cohort of 13 patients who had previously undergone splenectomy as salvage therapy for relapsing VL, 11 patients with HIV infection were investigated. This study compared the patients' complete blood cell count (CBC) and CD4+ and CD8+ cell counts before and after splenectomy with respect to spleen weight.
RESULTS: CBC was substantially improved after splenectomy, indicating hypersplenism. However, to the best of our knowledge, this is the first study to show that spleen mass is strongly and negatively correlated with CD4+ cell count (ρ = -0.71, P = 0.015).
CONCLUSIONS: This finding was unexpected, as the spleen is the most extensive lymphoid tissue and T-lymphocyte source. After reviewing the literature and reasoning, we hypothesized that the immunological failure was secondary to CD4+ loss initially by apoptosis in the spleen induced by productive HIV infection and, subsequently, by pyroptosis sustained by parasitic infection in spleen macrophages.
The purpose of this study was to investigate the role of polysaccharides from Ostrea rivularis Gloud (ORPs) in the progression of diabetic retinopathy (DR) and its anti-angiogenic effect on endothelial cell. Transgenic db/db mice with DR model were used to evaluate the protective effect of ORPs on retinal damage. It was found that ORPs could down-regulated levels of random blood glucose and fasting insulin, and further ameliorate retinal structure abnormalities as well as vascular network structure. Moreover, ORPs could reduce the expression of VEGF in retinal tissue and lessen pathological angiogenesis, thus slowing the progression of DR. In vitro, the proliferation, migration and tube formation of VGEF165-induced EA.hy926 cells were inhibited with ORPs administration. Furthermore, the expression of related proteins in the PI3K/AKT pathway and angiogenesis related factors were improved after ORPs intervention. Overall, these findings suggested that ORPs could effectively control the development of DR, and inhibit VGEF165-induced EA.hy926 cells proliferation, migration and tube formation, which effects might work through blocking the activation of PI3K/AKT signaling pathway.
Injectable compositions comprise a sterile mixture of a liquid carrier, a parenterally administrable drug, and from 0.1 to 10% (by weight of the drug) of a surface active agent selected from quaternary ammonium compounds, sulphosuccinates, polyoxyethylene condensates of long chain alkanols and their sulphuric acid monoesters, alkylated phenoxyethanols, and alkylated phenoxy (polyethanols), the drug being defined as one which acts at a site protected by a complex lipid barrier layer (e.g. at the surface of nerve tissue).  Specified drugs of this type are adrenalin, nor-adrenalin, curare (i.e. tube or bamboo curare, pot curare, and gourd or calabash curare), lidocaine, serotonin and digitoxin. Preferred surface active agents are compounds of the formula: <FORM:1083825/A5-A6/1> where R is C1 to C18 alkyl, particularly nonyl or octyl, and n has an average value of 1 to 30, particularly 6 when R is nonyl and 9 to 10 when R is actyl.  Carriers may be buffered isotonic aqueous solutions, sesame or peanut oil, aqueous propylene glycol or N,N-dimethyl-formamide.  The compositions may be sterilised by filtration.  The surface active agent is said to enhance the activity of the drug, and the invention includes a method for such enhancement wherein the drug and surface active agent are parenterally administered to warm blooded animals excluding human beings, either simultaneously and preferably together as a composition, or separately (e.g. up to 15 minutes apart) so that the surface active agent is present in the animal body during the period of activity of the drug.  Examples are given for this method, using Triton X-100 (Registered Trade Mark) and similar compounds as the surface active agent.
An increase in the prevalence of obesity due to lockdown and confinement linked to COVID-19 is observed. Variations in the nutritional status of schoolchildren from Jujuy are analyzed in relation to confinement due to COVID-19 (2019-2021) and its relationship with socio-demographic variables and the school environment. This is an observational, descriptive study. Data from 56,695 schoolchildren aged 6-18 years old is analyzed based on two temporary cuts (2019 pre-confinement and 2021 post-confinement). The nutritional status of schoolchildren (underweight, overweight, and obese) was established using the IOTF (International Obesity Task Force) criterion. The prevalence of each nutritional phenotype was estimated by sex and age group, considering the following independent variables: setting (rural/urban), school management system (public/private), geographic altitude, and percentage of households with unmet basic needs (UBN) in the place where they attend school. Multiple proportions contrast was performed using Fisher's test, a transition matrix ws produced and a statistical model of proportional odds was fitted. It was observed that between 2019 and 2021, the prevalence of underweight decreased and the prevalence of overweight and obesity increased significantly. In 2021, 67% of schoolchildren maintained the same nutritional category that they had in 2019, 21% gained weight and 12% lost weight. The model explains about 52% of the total variability observed. The factors that are significantly correlated in the model are school cycle, age, geographic altitude, school setting, and % of households with UBN. The results indicate that during the COVID-19 pandemic, there was a shift to the right in the distribution of the nutritional status categories of the schoolchildren population in Jujuy, with a decrease in the prevalence of underweight and an increase in the prevalence of overweight and obesity with variations related to age, school location, geographic altitude, and socioeconomic characteristics of the households in the place where the children attended school.
All surgeons will be asked to fill in a questionnaire, containing 5 questions, pertaining to the estimated risk of postoperative infection (within 30days). Thus there is a single arm and no comparison.
The invention provides an oligopeptide for promoting wound healing and application thereof, belonging to the technical field of biological medicines. The amino acid sequence of the oligopeptide for promoting wound healing is shown as SEQ ID NO. 1. The oligopeptide can promote proliferation and migration of NIH3T3 cells and accelerate wound healing of mice. Has advantages in promoting tissue regeneration, collagen deposition, angiogenesis and reducing wound inflammation. In conclusion, the oligopeptide disclosed by the invention can be used for remarkably promoting wound healing.
BACKGROUND: Cardiac open-heart surgery, which usually involves thoracotomy and cardiopulmonary bypass, is associated with a high incidence of postoperative mortality and adverse events. In recent years, sarcopenia, as a common condition in older patients, has been associated with an increased incidence of adverse prognosis.
METHODS: We conducted a search of databases including PubMed, Embase, and Cochrane, with the search date up to January 1, 2024, to identify all studies related to elective cardiac open-heart surgery in older patients. We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence.
RESULTS: A total of 12 cohort studies were included in this meta-analysis for analysis. This meta-analysis revealed that patients with sarcopenia had a higher risk of postoperative mortality. Furthermore, the total length of hospital stay and ICU stay were longer after surgery. Moreover, there was a higher number of patients requiring further healthcare after discharge. Regarding postoperative complications, sarcopenia patients had an increased risk of developing renal failure and stroke.
CONCLUSION: Sarcopenia served as a tool to identify high-risk older patients undergoing elective cardiac open-heart surgery. By identifying this risk factor early on, healthcare professionals took targeted steps to improve perioperative function and made informed clinical decisions.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023426026.
The invention discloses an oil-in-water emulsion-based medicinal preparation and its preparation method and application. The medicinal preparation comprises a drug molecule which is insoluble in water or vaseline oil, vaseline oil, at least a surfactant which can dissolve a component A but cannot be dissolved by water, at least a water-soluble surfactant and water. According to the invention, a special interface molecular layer which is positioned at an oil-water interface and is insoluble in water is used as a carrier of a water-insoluble medicine. The drug molecule in the interface molecular layer is insoluble in oil, and the effect of oil and water is to establish the interface molecular layer. Another effect of water is that water is used as a matrix in the overall prescription and stimulation to human tissues, especially eyes is minimized. When the interface molecular layer is contacted with diseased tissues of human body, the drug molecule can enter the diseased tissues from the interface molecular layer directly so as to save the slow process of the drug molecule diffusing from the inside of an oil phase to the surface of oil droplets and then passing through a high-energy barrier zone of the oil-water interface. Thus, the preparation provided by the invention has advantages of high drug effect, little drug use and low side-effect.
NEW MATERIAL:A compound expressed by formula I or salt thereof. USE:Vasodilator useful as treating agent of ischemic cardiac disease or cerebral blood flow improver. Has a low toxicity with a low side-effect. PREPARATION:At first, 2,3-pyridine dicarboxylic anhydride expressed by formula II is reacted with monoethanolamine in heating, preferably at 150-200 deg.C to obtain quinolinimide modification expressed by formula III (R is protecting group of H or OH). Next, 1-10 equiv. reducing agent (e.g. sodium boron hydride) is reacted with said compound in a solvent such as THF preferably at a temperature from -20 deg.C to 120 deg.C to obtain pyrrolopyridinone derivative expressed by formula IV. Furthermore, said derivative is reacted with nitrating agent (e.g. fuming nitric acid) at a temperature from -40 deg.C to 100 deg.C.
The present disclosure provides a multimedia editing method for assisting fitness. First, according to a fitness degree instruction, a first quantity of the first type parameters and a second quantity of the second type parameters are determined. Then, a segment parameter sequence is generated which contains the first segment parameter and the second segment parameter, and the first segment parameter and the second segment parameter are arranged in a disorder order. And selecting a first type of multi-media and a second type of multi-media from the database, wherein the first type of multi-media corresponds to the first type of multi-media parameters, and the second type of multi-media corresponds to the second type of multi-media parameters. And establishing a multimedia play list at least recording the first-class multimedia and the second-class multimedia. And in the multimedia playlist, the first segment multimedia and the second segment multimedia are arranged according to the sequence of the first segment parameter and the second segment parameter in the segment parameter sequence.
PURPOSE:To obtain a capsule particle with excellent dispersibility and solubility by preparing a capsule particle consisting of an inner layer and an outer layer having a film forming body and making the inner layer contg. an oily ingredient and a surfactant ingredient and making this oily ingredient under an emulsified and dispersed condition with no water separation. CONSTITUTION:A capsule particle consists of an inner layer and an outer layer having a film forming body and this inner layer contains an oily ingredient and a surfactant ingredient. In addition, emulsifying characteristics of the liq. of the content in this capsule exhibits a condition wherein 0.5g liq. of the content is fed in 2.5l water at 40 deg.C and the mixture is stirred by a stirring condition wherein 3 Y beaker 7 (the inner diameter is 14cm and the height is 20cm) and an anchor blade 9 (the blade diameter D is 5cm and the blade height H is 5cm and the blade width m is 1cm) are used and the upper face of the blade is 1cm lower from the water face and the number of rotation and the stirring time are respectively 150rpm and 30sec and the oily ingredient of this inner layer is kept under emulsified and dispersed condition and is not substantially separated from water at 40 deg.C. The capsule. particle thus obtd. exhibits good appearance, a sharp particle distribution, a uniform film thickness and excellent solubility.
Leucoderma Chinese materia medica preparation and its preparation method and application is treated the invention particularly discloses a kind of；It includes following raw material that the present invention, which treats leucoderma Chinese materia medica preparation: Chinese herbaceous peony, Radix Rehmanniae, peach kernel, radix bupleuri, the root of Dahurain angelica, cattail pollen, psoralea corylifolia, duckweed, donkey-hide gelatin, ramulus cinnamomi, Radix Curcumae, Radix Glycyrrhizae, trigone, the fruit of glossy privet, Herba Epimedii and radix cyathulae.The treatment leucoderma Chinese materia medica preparation preparation method comprises the steps of: that S1. gets out various raw material by formula；S2. various raw material are crushed, and is impregnated with water；S3. then, 70~80 DEG C of progress 35~45min of refluxing extraction take filtrate；S4. again by dregs of a decoction refluxing extraction 1~2 time under the conditions of 75~85 DEG C, 50~60min, takes filtrate every time, abandons filter residue；S5. then, merging filtrate, membrane filtration, and carry out concentration and medicinal extract is made；S6 again pelletized it by granulator, dry and whole grain to get.
BACKGROUND: Post-ischemia reperfusion can lead to oxidative stress and an increase in oxidative markers. Employing preventive strategies and antioxidant agents may help mitigate ischemia-reperfusion injury (IRI). The use of a tourniquet in extremity surgery has been associated with IRI. This study aims to investigate the impact of three different approaches- brachial plexus block, total intravenous anesthesia (TIVA), and inhalation anesthesia-on IRI during upper extremity surgery using a tourniquet.
METHODS: Patients aged 18 to 45 with American Society of Anesthesiologists (ASA) I-II scores were randomly assigned to one of three groups: Group A received an axillary block with bupivacaine; Group I underwent inhalation anesthesia with sevoflurane; and Group T received TIVA with propofol and remifentanil infusion. Blood samples were collected to measure glucose, lactate, total anti-oxidant status (TAS), total oxidant status (TOS), and ischemia-modified albumin (IMA) levels at various time points: before anesthesia (t1), 1 minute before tourniquet release (t2), 20 minutes after tourniquet release (t3), and 4 hours after tourniquet release (t4).
RESULTS: In Group I, lactate levels at t3, and glucose levels at t2 and t3, were higher compared to the other groups. Group A exhibited lower IMA levels at t2, t3, and t4 than the other groups. Additionally, Group I had lower IMA levels at t2, t3, and t4 compared to Group T. TAS levels were higher in Group I at t2, t3, and t4 compared to the other groups. TOS levels at t2 and t3 were lower in Group A than in Group I.
CONCLUSION: Axillary anesthesia results in a sympathetic block, promoting better perfusion of the upper extremity. This study demonstrated lower levels of oxidative stress markers with axillary plexus block. Therefore, these results suggest that the axillary block has the potential to mitigate IRI.
Aβ plaques are a main feature of Alzheimer's disease, and pathological alterations especially in their microenvironment have recently come into focus. However, a holistic imaging approach unveiling these changes and their biochemical nature is still lacking. In this context, we leverage confocal Raman microscopy as unbiased tool for non-destructive, label-free differentiation of progressive biomolecular changes in the Aβ plaque microenvironment in brain tissue of a murine model of cerebral amyloidosis. By developing a detailed approach, overcoming many challenges of chemical imaging, we identify spatially-resolved molecular signatures of disease-associated structures. Specifically, our study reveals nuclear condensation, indicating cellular degeneration, and increased levels of cytochrome c, showing mitochondrial dysfunction, in the vicinity of Aβ plaques. Further, we observe severe accumulation of especially unsaturated lipids. Thus, our study contributes to a comprehensive understanding of disease progression in the Aβ plaque microenvironment, underscoring the prospective of Raman imaging in neurodegenerative disorder research.
The present invention relates to fusion protein (HSA-ADI) for human serum albumin (HSA) and mycoplasma arginine deacylase, a method for preparing the protein and application to preparing medicine for treating tumors, such as hepatoma, etc. The present invention adopts a eukaryotic expression philosophy and technology to clone the gene of the human serum albumin by a PCR method and chemically synthesize the gene of the mycoplasma arginine deacylase. A eukaryotic expression vector is used for constructing recombinant plasmids and converting eukaryotic cells to obtain a strain for stably expressing HSA-ADI. After the strain is fermented, fermentation liquid supernatant is purified by the methods of dialysis, ion exchange, a molecular sieve, etc. New molecules obtained by bioactivity examining verification have ADI activity. A protective agent is added to the purified product to be prepared into a freeze-dried pharmaceutical preparation. As proved by pharmacodynamics research results, the preparation can be used for the treatment of liver cancer, mammary cancer, melanoma, leukemia, lymphoma, glossopharyngeum tumor, etc.
<P>PROBLEM TO BE SOLVED: To provide a new antiseptic, especially the antiseptic expressing excellent antiseptic action when used for water-based compositions such as an ophthalmic agent and the like, and a water-based composition provided with excellent antiseptic action.  <P>SOLUTION: The antiseptic comprises (A) at least one species of compounds selected from diphenhydramine, chlorpheniramine or their salts combined with (B) boric acid and/or a boric acid salt. The antiseptic is prepared by combining 1 pt.wt. diphenhydramine or its salt as the total amount and 0.5-10,000 pts.wt. boric acid and/or its salt as the total amount, or 1 pt.wt. chlorpheniramine or its salt as the total amount and 0.5-10,000 pts.wt. boric acid and /or its salt as the total amount.  <P>COPYRIGHT: (C)2006,JPO&NCIPI